Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2023; 29(20): 3168-3184
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3168
Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
Jia-Lin Wu, Jun-Yang Luo, Zai-Bo Jiang, Si-Bo Huang, Ge-Run Chen, Hui-Ying Ran, Qi-Yue Liang, Ming-Sheng Huang, Li-Sha Lai, Jun-Wei Chen
Jia-Lin Wu, Jun-Yang Luo, Zai-Bo Jiang, Ming-Sheng Huang, Jun-Wei Chen, Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China
Si-Bo Huang, Ge-Run Chen, The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China
Hui-Ying Ran, Qi-Yue Liang, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China
Li-Sha Lai, Department of Radiology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510010, Guangdong Province, China
Author contributions: Jiang ZB, Chen JW, and Huang MS contributed to conceptualization; Wu JL, Huang SB, Chen GR, Ran HY, and Liang QY contributed to acquisition of data, formal analysis (statistics), and visualization; Wu JL and Luo JY contributed to writing-original draft; Chen JW contributed to writing-review and editing; Huang MS, Jiang ZB, Lai LS, and Chen JW contributed to supervision; and all authors read and approved the final version of the manuscript.
Supported by the National Natural Science Foundation of China, No. 82072035; and Science and Guangzhou Planned Project of Science and Technology, No. 202102010028.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Ethical Committee of the Third Affiliated Hospital of Sun Yat-sen University (approval No. II2023-027-11).
Informed consent statement: Written informed consent of the patients was waived because of the retrospective nature of this study.
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Data sharing statement: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Wei Chen, MD, Professor, Interventional Radiologist, Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. chenjw53@mail.sysu.edu.cn
Received: March 3, 2023
Peer-review started: March 3, 2023
First decision: March 24, 2023
Revised: April 2, 2023
Accepted: April 24, 2023
Article in press: April 24, 2023
Published online: May 28, 2023
Core Tip

Core Tip: We developed and validated a prognostic nomogram based on inflammation-related biomarkers for patients with unresectable hepatocellular carcinoma after conversion therapy. The proposed conversion therapy model shows increased accuracy, good clinical utility, and better prognostic performance compared with conventional staging systems. Based on the total predictive risk scores, the patients were classified into two groups: low-risk (score < 196) and high-risk group (score ≥ 196), to guide postoperative adjuvant interventions and follow-ups. Furthermore, we have made this prognostic nomogram online for free use (https://ctmodelforunresectablehcc.shinyapps.io/DynNomapp/).